LONDON and ANN ARBOR, Michigan, June 21, 2011 /PRNewswire/ --
NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first cerebrospinal fluid (CSF) multiple protein (multiplex) assay, csfdiscovery43, for central nervous system (CNS) biomarker discovery and qualification. The assay simultaneously measures 43 human CSF proteins that are thought to have potential as biomarkers in CNS diseases, particularly Alzheimer's, Parkinson's, multiple sclerosis and ALS diseases. The launch of csfdiscovery43is the next step in NextGen Sciences strategy of becoming a leading player in the growing CNS and oncology biomarker markets.
NextGen's assay is based upon its multiple reaction monitoring (MRM) mass spectrometry platform, and generates high quality reproducible data that companies can use in their drug and diagnostic development programmes. In addition to the CNS disease focus, the assay can be used for early-stage biomarker discovery and qualification in other disease areas e.g. traumatic brain injury (TBI). NextGen expects to continue to add proteins to the csfdiscovery43assay, in addition to developing other disease-focused assay panels, both as proprietary products and with other companies through partnerships and collaborations.
Klaus Rosenau, Chairman and CEO of NextGen Group, commented,
'The release of csfdiscovery43is the next defining step in
the development of NextGen Sciences' biomarker business, following
its reorganization and release of the plasmadiscovery41
|SOURCE NextGen Group plc|
Copyright©2010 PR Newswire.
All rights reserved